CRYOLIFE, INC. (NYSE:CRY) Files An 8-K Results of Operations and Financial Condition

Item 2.02Results of Operations and Financial Condition.

On April 26, 2017, CryoLife, Inc. (CryoLife or the Company)
issued a press release announcing its financial results for the
quarterended March 31, 2017. CryoLife hereby incorporates by
reference herein the information set forth in its press release
dated April 26, 2017, a copy of which is attached hereto as
Exhibit 99.1. Except as otherwise provided in the press release,
the press release speaks only as of the date of such press
release and it shall not create any implication that the affairs
of CryoLife have continued unchanged since such date.

The information provided to this Item 2.02 is to be considered
furnished to Item 2.02 of Form 8-K and shall not be deemed to be
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of
that Section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended, nor shall it be deemed incorporated by
reference into any of CryoLifes reports or filings with the
Securities and Exchange Commission, whether made before or after
the date hereof, except as expressly set forth by specific
reference in such report or filing.

Except for the historical information contained in this report,
the statements made by CryoLife are forward-looking statements
that involve risks and uncertainties. All such statements are
subject to the safe harbor created by the Private Securities
Litigation Reform Act of 1995. CryoLifes future financial
performance could differ significantly from the expectations of
management and from results expressed or implied in the press
release. Please refer to the last paragraph of the text portion
of the press release for further discussion about forward-looking
statements. For further information on risk factors, please refer
to Risk Factors contained in CryoLifes Form 10-K filed for the
year ended December 31, 2016 and its subsequent filings with the
Securities and Exchange Commission, as well as in the press
release attached as Exhibit 99.1 hereto. CryoLife disclaims any
obligation or duty to update or modify these forward-looking
statements.

Section 9Financial Statements and Exhibits.

Item 9.01(d) Exhibits.

(a) Financial Statements.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Shell Company Transactions.

Not applicable.

(d) Exhibits.

*This exhibit is furnished, not filed.

About CRYOLIFE, INC. (NYSE:CRY)

CryoLife, Inc. (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol). The Preservation Services segment preserves cardiac and vascular tissues. The Company’s surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), and PerClot, an absorbable powdered hemostat, which the Company distributes internationally for Starch Medical, Inc. (SMI). Its CardioGenesis cardiac laser therapy product line includes a laser console system and single-use, fiber-optic handpieces.

CRYOLIFE, INC. (NYSE:CRY) Recent Trading Information

CRYOLIFE, INC. (NYSE:CRY) closed its last trading session up +0.50 at 16.75 with 225,539 shares trading hands.